...
首页> 外文期刊>Platelets >PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy
【24h】

PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy

机译:PlaCor PRT测量单抗和双抗血小板治疗的稳定患者的剪切活化血小板聚集物形成

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Shear forces play a key role in thrombus formation and shear-based tests may better reflect physiological conditions in vivo compared with agonist-based tests. We evaluated the PlaCor PRT?, a novel platelet reactivity test based on shear-induced platelet aggregation, in patients with stable coronary artery disease (CAD) treated with single (SAPT) and dual antiplatelet therapy (DAPT). We examined 100 patients with multiple risk factors for CAD and/or documented stable CAD: 38 treated with SAPT, aspirin 100 mg qd, 62 treated with DAPT, aspirin 100 mg + clopidogrel 75 mg qd, compared with age- and sex-matched healthy volunteers without antiplatelet therapy (HV, n = 35). Measures of shear-induced platelet aggregation were performed with the PlaCor PRT?. In 25 patients in SAPT, the PlaCor test was also performed before and after a 12-hour-loading dose of clopidogrel 600 mg. The mean ± SD PRT time (seconds) in HV was 78 ± 13 and was significantly lower compared with SAPT (118 ± 16, p = 0.030) and to DAPT patients (242 ± 11, p < 0.0001). A statistically significant difference was also reported between SAPT and DAPT patients (p < 0.0001). After a loading dose of clopidogrel, the PRT time of SAPT patients increased significantly from 112 ± 20 to 254 ± 17, p < 0.0001. 2.7 and 26% of patients were considered as "poor responders" to single and dual antiplatelet therapy, respectively. This study shows that in patients with multiple risk factors for CAD and/or documented stable CAD, SAPT and DAPT play an important role in reducing platelet aggregation mediated by shear forces as evaluated with the novel PlaCor PRT?. Further studies will be required to confirm and assess the extent of these findings in patients with acute coronary syndromes.
机译:剪切力在血栓形成中起关键作用,与基于激动剂的测试相比,基于剪切的测试可能更好地反映体内的生理状况。我们评估了以单抗(SAPT)和双重抗血小板治疗(DAPT)治疗的稳定型冠状动脉疾病(CAD)患者中基于剪切诱导的血小板聚集的新型血小板反应性试验PlaCor PRT?我们检查了100名具有多种CAD危险因素和/或已记录的稳定CAD的患者:与年龄和性别相匹配的健康人群相比,38例接受SAPT,阿司匹林100 mg qd,62例接受DAPT,阿司匹林100 mg +氯吡格雷75 mg qd没有抗血小板治疗的志愿者(HV,n = 35)。用PlaCor PRT 2进行剪切诱导的血小板聚集的测量。在25例SAPT患者中,在12小时负荷剂量的600mg氯吡格雷前后也进行了PlaCor测试。 HV的平均±SD PRT时间(秒)为78±13,与SAPT(118±16,p = 0.030)和DAPT患者(242±11,p <0.0001)相比,明显更低。 SAPT和DAPT患者之间也报告了统计学上的显着差异(p <0.0001)。服用氯吡格雷后,SAPT患者的PRT时间从112±20显着增加至254±17,p <0.0001。分别有2.7%和26%的患者被认为是单抗和双重抗血小板治疗的“不良反应”。这项研究表明,对于具有多种CAD危险因素和/或已记录的稳定CAD的患者,SAPT和DAPT在减少由剪切力介导的血小板凝集方面起着重要作用,如新型PlaCor PRT?所评估的那样。将需要进一步的研究来确认和评估急性冠脉综合征患者的这些发现的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号